Yazar "Yildirim, Murat" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis
    (Galenos Publ House, 2024) Atas, Uenal; Salim, Ozan; Iltar, Utku; Yucel, Orhan Kemal; Eroglu, Ayse Hilal Kuecuekdiler; Aslan, Vedat; Yildirim, Murat
    Objective: In this study, we aimed to obtain real-life data on the use of antimyeloma agents, which significantly increase overall survival (OS) in multiple myeloma (MM) patients, in primary plasma cell leukemia (pPCL) patients with poor prognosis. Materials and Methods: Data from 53 patients who were diagnosed with pPCL between 2011 and 2020 and who used at least one proteasome inhibitor (PI) and/or immunomodulatory (IMID) agent were analyzed retrospectively. Depending on the year of the pPCL diagnosis, 20% leukocytes or >= 2x109/L plasma cells in the peripheral blood was used as a diagnostic criterion. Results: The median age of the patients was 58 years and 23 (43.4%) patients were over 65 years of age. For first-line treatment, PI or IMID alone was used by 31 (58.5%) patients, and PI and IMID were used simultaneously by 15 (28.3%) patients. Additionally, 21 (39.6%) patients received transplantation and 13 (24.5%) patients received maintenance treatment. The median progression-free survival was 4 (range: 1-42) months. When patients whose primary disease was refractory to first-line therapy were excluded, the duration of treatment was 6.5 months. The median OS was 15 months with a median follow-up duration of 15 months. Only 7 (13.2%) of the patients were alive at the last follow-up visit. Those with higher (3 2- microglobulin levels and International Staging System stage 3 and non-transplant patients receiving first-line treatment had shorter OS (p=0.005, p=0.02, and p=0.008, respectively). The concomitant use of PIs and IMIDs, the addition of chemotherapy to induction therapy, and the response to induction therapy or maintenance therapy did not affect OS. Conclusion: In this study, as in previous similar studies, we could not see an increased survival trend in pPCL, which is observed in MM. New studies are needed for pPCL, which is likely to increase with new diagnostic criteria, based on current agents and information from MM.
  • Küçük Resim Yok
    Öğe
    The role of identification with all humanity in the relationship between social dominance orientation and intergroup anxiety
    (Emerald Group Publishing Ltd, 2025) Cagis, Zafer Guney; Aksoy, Seyhmus; Alkhulayfi, Abdulmohsen Mohammed Abdullah; Aziz, Izaddin Ahmad; Gomez-Salgado, Juan; Yildirim, Murat
    PurposeThis study aims to investigate how identifying with all humanity (IWAH), a feeling of connection and compassion towards all people, impacts intergroup relations. Specifically, it examines whether IWAH mediates the link between social dominance orientation (SDO) and intergroup anxiety.Design/methodology/approachThe sample included 304 adults from T & uuml;rkiye (61.2% male; age range: 18-64, M = 29.83, SD = 8.38), who completed an online survey including the SDO, intergroup anxiety and the IWAH scale.FindingsResults showed that higher SDO was linked to lower IWAH and greater intergroup anxiety. In contrast, higher IWAH was associated with reduced intergroup anxiety. Mediation analysis confirmed that IWAH significantly mediated the relationship between SDO and intergroup anxiety.Originality/valueThese findings suggest that fostering a broader human identity may buffer the negative effects of social dominance on intergroup relations. This study contributes to research highlighting IWAH as a potential pathway to reducing intergroup tensions and promoting global solidarity.